Why does Control-IQ technology use 160 mg/dL as the value to begin increasing basal insulin?
Control-IQ technology will increase basal insulin if the sensor reading is predicted to be above 160mg/dL in the next 30 minutes. 160 mg/dL was calculated to be the glucose level to begin to increase basal insulin delivery to help prevent glucose from rising above 180 mg/dL. If glucose continues to rise and is still predicted to be above 180 mg/dL in 30 minutes, Control-IQ technology can deliver an automatic correction bolus to help minimize time spent above 180mg/dl.
Why does Control-IQ technology use 112.5 mg/dL as the value to begin decreasing basal insulin?
Control-IQ technology will decrease basal insulin if the sensor reading is predicted to be below 112.5mg/dL in the next 30 minutes. 112.5 mg/dL was calculated to be the glucose level to begin the decrease of basal insulin delivery. This is the level where Control-IQ technology decreases basal delivery to help prevent hypoglycemia. This is not the level that Control-IQ technology stops insulin delivery, which begins when glucose is predicted to reach or go below 70 mg/dl within the next 30 minutes.
Indications for Use:
t:slim X2 insulin pump
The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin. The pump is indicated for use in individuals 6 years of age and greater.
Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.
|WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.
Users of the t:slim X2 pump and Control-IQ technology must:
- be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use;
- test blood glucose levels as recommended by their healthcare provider;
- demonstrate adequate carb-counting skills;
- maintain sufficient diabetes self-care skills;
- see healthcare provider(s) regularly; and
- have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders;